UBS cuts Engene Holdings stock price target on trial costs
#UBS #Engene Holdings #stock price target #trial costs #clinical trials #financial impact #investment
📌 Key Takeaways
- UBS lowered its stock price target for Engene Holdings due to increased trial costs.
- The adjustment reflects concerns over financial impacts from ongoing legal proceedings.
- Engene Holdings faces higher expenses from clinical trials affecting its valuation.
- The revised target signals potential investor caution regarding the company's near-term performance.
🏷️ Themes
Financial Analysis, Healthcare
Entity Intersection Graph
No entity connections available yet for this article.